New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:22 EDTTSN, HITT, MRK, ODP, ALNY, HSH, DG, ACHN, AZN, NSR, ADI, FDO, IDIX, CGIXOn The Fly: Pre-market Movers
HIGHER: Idenix (IDIX), up more than 230% after Merck (MRK) acquires the company for $24.50 per share in cash of $3.85B. Idenix peer Achillion (ACHN) is up 35% after Merck's purchase... Hittite Microwave (HITT), up 29% after Analog Devices (ADI) agrees to acquire the company for $78 per share in cash... Family Dollar (FDO), up 11.6% following upgrade at Jefferies after Carl Icahn reported a 9.4% stake in the company. Dollar General (DG), which is being seen as potentially urged as a merger target for Family Dollar based on Icahn's stake, is up 8.6% after the news... Hillshire Brands (HSH), up 4.7% after Tyson Foods (TSN) submits unilaterally binding offer to acquire the company for $8.55B... Office Depot (ODP), up 4.6% after Barron's says shares could jump over 50%... Cancer Genetics (CGIX), up 6.4% after announcing partnership with AstraZeneca (AZN). LOWER: NeuStar (NSR), down 6.3% after calling FCC posting of confidential email "troubling"... Alnylam (ALNY), down 5.8% after presenting ALN-CC5 new pre-clinical data.
News For IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:43 EDTMRK, AZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
09:37 EDTMRKActive equity options trading
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
08:03 EDTALNYAlnylam adds ALN-HDV, ALN-PDL to hepatic infectious disease pipeline
Subscribe for More Information
07:56 EDTCGIXCancer Genetics receives second patent for FHACT
Cancer Genetics announced that it has received a second U.S. patent covering its proprietary FISH-based HPV-Associated Cancer Test, or FHACT, for cervical cancer detection in patients. FHACT is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.
05:56 EDTACHNStocks with implied volatility above IV index mean; GME ACHN
Subscribe for More Information
November 10, 2014
16:44 EDTACHNOn The Fly: Closing Wrap
Subscribe for More Information
12:24 EDTACHNOn The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday. The averages opened mixed, but very close to the flat line, and have continued to drift slowly higher from that point. There is little to stand in the way of the market’s drift, as the economic calendar is quiet, the earnings season is winding down, and the most closely watched geopolitical situations are currently status quo. ECONOMIC EVENTS: In the U.S., little of note was on the economic calendar. The Federal Reserve's newly introduced Labor Market Conditions Index was flat at 4 in October. The Fed started updating estimates of the LMCI every month beginning with last month. COMPANY NEWS: Shares of Netflix (NFLX) advanced about 1% after xxx President Barack Obama publicly urged the Federal Communications Commission to implement the "strongest possible rules" to protect net neutrality. In response, Verizon (VZ) said it supports the open Internet and continues to believe that the "light-touch regulatory approach in place for the past two decades has been central to the Internet’s success," adding that it believes the reclassification Obama called for would "apply 1930s-era utility regulation to the Internet" and be a "radical reversal of course" that would threaten great harm to an open Internet, competition and innovation." A number of Internet Service Providers, including Comcast (CMCSA), Time Warner Cable (TWC), Charter (CHTR) and Cablevision (CVC), moved lower after Obama weighed in on the hot-button issue. MAJOR MOVERS: Among the notable gainers was Achillion Pharmaceuticals (ACHN), which rose 22% after the company presented data from the ongoing Phase 2 study of its Hepatitis C virus treatment at the Annual Meeting of the American Association for the Study of Liver Diseases, or AASLD. Also higher was Dean Foods (DF), which rose more than 13% after the dairy products distributor’s third quarter results, as well as its fourth quarter and full year profit outlook, surpassed analysts’ consensus estimates. Among the noteworthy losers was Rayonier (RYN), which dropped 13% after management determined that there was a material weakness in the company's internal controls, restated certain previously made financial statements, and cut its dividend reflecting expectations of reduced cash available for distribution due to lower expected annual harvest levels. INDEXES: Near midday, the Dow was up 18.55, or 0.11%, to 17,592.48, the Nasdaq was up 10.77, or 0.23%, to 4,643.30, and the S&P 500 was up 4.01, or 0.2%, to 2,035.93.
12:09 EDTTSNUSDA raises 2014 meat production forecast, lowers 2015
Subscribe for More Information
10:17 EDTACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:35 EDTACHNActive equity options trading
Subscribe for More Information
09:20 EDTMRK, ACHNOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:58 EDTCGIXCancer Genetics reports adjusted Q3 EPS (41c), consensus (48c)
Reports Q3 revenue $3.22M, consensus $3.18M.
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naďve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
14:09 EDTALNYAlnylam management to meet with Needham
Subscribe for More Information
12:02 EDTACHNAchillion reports 100% SVR12 in a Phase 2 combination study with ACH-3102
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use